Physician preferences for non-metastatic castration-resistant prostate cancer treatment

BACKGROUND: Recent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar efficacy but differ in safety profiles. We used a discrete choice experiment to exp...

Full description

Saved in:
Bibliographic Details
Published in:BMC Urol
Main Authors: Srinivas, Sandy, Mohamed, Ateesha F., Appukkuttan, Sreevalsa, Botteman, Marc, Ng, Xinyi, Joshi, Namita, Horodniceanu, Erica, Waldeck, A. Reginald, Simmons, Stacey J
Format: Artigo
Language:Inglês
Published: BioMed Central 2020
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310549/
https://ncbi.nlm.nih.gov/pubmed/32571276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-020-00631-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items